[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 809, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith M.D., Ph.D.", "age": 63, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1347967, "exercisedValue": 10163472, "unexercisedValue": 51843852}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 725633, "exercisedValue": 849639, "unexercisedValue": 2896538}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 62, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 897933, "exercisedValue": 3021392, "unexercisedValue": 16625696}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 64, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 951933, "exercisedValue": 4257259, "unexercisedValue": 11511893}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 55, "title": "Executive Vice President of Development", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 701200, "exercisedValue": 0, "unexercisedValue": 13540803}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 44, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 107.39, "open": 120.0, "dayLow": 109.77, "dayHigh": 121.615, "regularMarketPreviousClose": 107.39, "regularMarketOpen": 120.0, "regularMarketDayLow": 109.77, "regularMarketDayHigh": 121.615, "payoutRatio": 0.0, "beta": 0.99, "forwardPE": -18.87645, "volume": 20501717, "regularMarketVolume": 20501717, "averageVolume": 3012179, "averageVolume10days": 6133360, "averageDailyVolume10Day": 6133360, "bid": 70.72, "ask": 82.29, "bidSize": 2, "askSize": 2, "marketCap": 22935461888, "fiftyTwoWeekLow": 29.17, "fiftyTwoWeekHigh": 121.615, "allTimeHigh": 121.615, "allTimeLow": 14.08, "fiftyDayAverage": 75.0632, "twoHundredDayAverage": 48.993027, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 21418924032, "profitMargins": 0.0, "floatShares": 173962693, "sharesOutstanding": 193319805, "sharesShort": 15070669, "sharesShortPriorMonth": 17485484, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.078, "heldPercentInsiders": 0.01872, "heldPercentInstitutions": 1.02367, "shortRatio": 6.93, "shortPercentOfFloat": 0.0828, "impliedSharesOutstanding": 193319805, "bookValue": 8.418, "priceToBook": 14.093609, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -960977984, "trailingEps": -5.18, "forwardEps": -6.28508, "enterpriseToEbitda": -20.798, "52WeekChange": 1.7869391, "SandP52WeekChange": 0.19362879, "quoteType": "EQUITY", "currentPrice": 118.64, "targetHighPrice": 147.0, "targetLowPrice": 72.0, "targetMeanPrice": 88.21053, "targetMedianPrice": 85.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 1931507968, "totalCashPerShare": 9.991, "ebitda": -1029836992, "totalDebt": 414969984, "quickRatio": 7.864, "currentRatio": 8.051, "debtToEquity": 25.986, "returnOnAssets": -0.32287, "returnOnEquity": -0.6076, "grossProfits": -880484992, "freeCashflow": -438248512, "operatingCashflow": -761793024, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Revolution Medicines, Inc.", "longName": "Revolution Medicines, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "postMarketChangePercent": -1.635201, "postMarketPrice": 116.7, "postMarketChange": -1.9400024, "regularMarketChange": 11.25, "regularMarketDayRange": "109.77 - 121.615", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3012179, "fiftyTwoWeekLowChange": 89.47, "fiftyTwoWeekLowChangePercent": 3.0671923, "fiftyTwoWeekRange": "29.17 - 121.615", "fiftyTwoWeekHighChange": -2.9749985, "fiftyTwoWeekHighChangePercent": -0.024462432, "fiftyTwoWeekChangePercent": 178.69391, "earningsTimestamp": 1762376400, "earningsTimestampStart": 1762376400, "earningsTimestampEnd": 1762376400, "earningsCallTimestampStart": 1762378200, "earningsCallTimestampEnd": 1762378200, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -5.18, "epsForward": -6.28508, "epsCurrentYear": -5.54092, "priceEpsCurrentYear": -21.411608, "fiftyDayAverageChange": 43.576797, "fiftyDayAverageChangePercent": 0.58053476, "twoHundredDayAverageChange": 69.64697, "twoHundredDayAverageChangePercent": 1.4215691, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "corporateActions": [], "postMarketTime": 1768006799, "regularMarketTime": 1767992401, "exchange": "NMS", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": 10.4758, "regularMarketPrice": 118.64, "marketState": "CLOSED", "displayName": "Revolution Medicines", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]